Skip to main content
no upcoming events

Please check back with us.

PIPELINE > TRIAL OVERVIEW

Trial Information
Molecule Overview
VEGF Receptor-2 Antagonist
Ramucirumab
VEGF-Receptor-2-Antagonist

Adams RH and Alitalo K1; Hicklin DJ and Ellis LM2

Target

Angiogenesis is a tightly regulated, multiple-step process, which results in the formation of new blood vessels from preexisting vasculature and is an important component in the development and progression of malignant disease. Signaling by vascular endothelial growth factor (VEGF) receptor-2 in endothelial cells plays a role in inducing normal and pathologic angiogenesis and is activated by binding of ligands VEGF-A, VEGF-C, and VEGF-D.1-3

Molecule

Ramucirumab is a human IgG1 monoclonal antibody receptor antagonist that has been shown in preclinical studies to bind to and block the activation of VEGF receptor-2 by preventing the binding of VEGF receptor ligands VEGF-A, VEGF-C, and VEGF-D.4,5

Clinical Development

Ramucirumab is being investigated in clinical trials in patients with metastatic non-small cell lung cancer, biliary tract cancer, or pediatric sarcoma.

References

  1. Adams RH, Alitalo K. Nat Rev Mol Cell Biol. 2007;8(6):464-478.
  2. Hicklin DJ, Ellis LM. J Clin Oncol. 2005;23(5):1011-1027.
  3. Olsson AK, et al. Nat Rev Mol Cell Biol. 2006;7(5):359-371.
  4. Lu D, et al. J Biol Chem. 2003;278(44):43496-43507.
  5. Zhu Z, et al. Leukemia. 2003;17(3):604-611.
For information on trial enrollment, locations, and more, call 1-800-545-5979.
REQUEST A MEDICAL SCIENCE LIAISON

or visit www.clinicaltrials.gov for more information on this trial